Christopher L. Moertel, MD

Christopher Moertel, MD is the Kenneth and Betty Jayne Dahlberg Professor of Pediatrics in the University of Minnesota School of Medicine. He is the medical director of the Katie Hageboeck Children's Cancer Research Fund Clinic and leads the Pediatric Brain Tumor Program at the Comprehensive Neurofibromatosis Clinic.

Articles by Christopher L. Moertel, MD

Christopher L. Moertel, MD, professor, Pediatric Neuro-Oncology Fellowship Program director, Division of Pediatric Hematology/Oncology, faculty member, Department of Pediatrics, medical director, Pediatric Neuro-Oncology and Neurofibromatosis Programs, co-medical director, Katie Hageboeck Children’s Cancer Research Fund Clinic, clinical neuro-oncology leader, Brain Tumor Program, Kenneth and Betty Jayne Dahlberg Professor, University of Minnesota School of Medicine

MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

ByChristopher L. Moertel, MD

May 12th 2025

Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN

ByChristopher L. Moertel, MD

April 3rd 2025

Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

ByChristopher L. Moertel, MD

February 20th 2025

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

Dr Moertel on the FDA Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

ByChristopher L. Moertel, MD

February 11th 2025

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Latest Updated Articles

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN
Published: April 3rd 2025 | Updated:

Christopher L. Moertel, MD

Articles by Christopher L. Moertel, MD

MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

Dr Moertel on the FDA Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

Latest Updated Articles

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients With Advanced NSCLC Live Longer